Metagenomic Analysis of Flaviviridae in Mosquito Viromes Isolated From Yunnan Province in China Reveals Genes From Dengue and Zika Viruses

Xiao, Pengpeng; Han, Jin‐Hee; Zhang, Ying; Li, Chenghui; Guo, Xin; Wen, Sijian; Tian, Mingyao; Li, Yiquan; Wang, Maopeng; Líu, Hao; Ren, Jin; Zhou, Hongning; Lu, Huijun; Jin, Ningyi

doi:10.3389/fcimb.2018.00359

Cited by 33 publications

(37 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In order to ensure comparability with what humans receive, future studies may need to test various dosing regimens. Fu et al and Xiao et al identified ZIKV in mosquitoes in Guizhou province and Yunnan province (Fu et al 2017;Xiao et al 2018), indicating that ZIKV is present in China. Therefore, it is inevitable that JEV and ZIKV co-circulate.…”

Section: Discussionmentioning

confidence: 99%

T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine

Wang

Zhen

Turtle

et al. 2020

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

Zika virus (ZIKV) and Japanese encephalitis virus (JEV) are closely related to mosquito-borne flaviviruses. Japanese encephalitis (JE) vaccine SA14-14-2 has been in the Chinese national Expanded Program on Immunization since 2007. The recent recognition of severe disease syndromes associated with ZIKV, and the identification of ZIKV from mosquitoes in China, prompts an urgent need to investigate the potential interaction between the two. In this study, we showed that SA14-14-2 is protective against ZIKV infection in mice. JE vaccine SA14-14-2 triggered both Th1 and Th2 cross-reactive immune responses to ZIKV; however, it was cellular immunity that predominantly mediated cross-protection against ZIKV infection. Passive transfer of immune sera did not result in significant cross-protection but did mediate antibody-dependent enhancement in vitro, though this did not have an adverse impact on survival. This study suggests that the SA14-14-2 vaccine can protect against ZIKV through a cross-reactive T cell response. This is vital information in terms of ZIKV prevention or precaution in those ZIKV-affected regions where JEV circulates or SA14-14-2 is in widespread use, and opens a promising avenue to develop a novel bivalent vaccine against both ZIKV and JEV. Key points • JEV SA14-14-2 vaccine conferred cross-protection against ZIKV challenge in mice. • T cell immunity rather than antibody mediated the cross-protection. • It provides important information in terms of ZIKV prevention or precaution.

show abstract

Section: Discussionmentioning

confidence: 99%

T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine

Wang

Zhen

Turtle

et al. 2020

Appl Microbiol Biotechnol

View full text Add to dashboard Cite

show abstract

“…and Xiao et al . identified ZIKV in mosquitoes in Guizhou province and Yunnan province (40, 41), indicating that ZIKV is present in China. Therefore, it is inevitable that JEV and ZIKV co-circulate.…”

Section: Discussionmentioning

confidence: 99%

Cross-Protection Against Zika Virus Infection Conferred by a Live Attenuated Japanese Encephalitis SA14-14-2 Vaccine

Wang

Zhen

Turtle

et al. 2020

Preprint

View full text Add to dashboard Cite

24Zika virus (ZIKV) and Japanese encephalitis virus (JEV) are closely related 25 mosquito-borne flaviviruses. Japanese encephalitis (JE) vaccine SA14-14-2 has been in 26 the Chinese national Expanded Program on Immunization since 2007. The recent 27 recognition of severe disease syndromes associated with ZIKV, and the identification of 28 ZIKV from mosquitoes in China, prompts an urgent need to investigate the potential 29 interaction between the two. In this study, we showed that SA14-14-2 is protective against 30 ZIKV infection in mice. JE vaccine SA14-14-2 triggered both Th1 and Th2 cross-reactive 31 immune responses to ZIKV; however, it was cellular immunity that predominantly 32 mediated cross-protection against ZIKV infection. Passive transfer of immune sera did not 33 result in significant cross-protection, but did mediate antibody dependent enhancement in 34 vitro, though this did not have an adverse impact on survival. This study suggests that 35 SA14-14-2 vaccine can protect against ZIKV through a cross-reactive T cell response. 36This is vital information in terms of ZIKV prevention or precaution in those ZIKV-affected 37 regions where JEV circulates or SA14-14-2 is in widespread use, and opens a promising 38 avenue into developing a novel bivalent vaccine against both ZIKV and JEV. 40Importance 43 Japanese encephalitis is a controllable disease in many countries in Asia, especially in 44 China, where many people have Japanese encephalitis virus (JEV) immunity due to 45 extensive JEV vaccination campaigns or natural exposure. Live-attenuated SA14-14-2 46 strain is a safe and effective vaccine recommended by the World Health Organization and 47 has been vaccinated more than 600 million doses since 1989. As the prevalence of Zika 48 virus (ZIKV) and rising risk in above regions, the cross-reactive immune response 49 between these two antigenically closely related flaviviruses, JEV and ZIKV, should also be 50 fully recognized, which is presumed to be based on those ambiguous cross-reactive 51 immunity between dengue virus and ZIKV. In this study, we found that JEV SA14-14-2 52 vaccine conferred cross-protection against ZIKV challenge in mice, which is mainly due to 53 cellular immunity rather than neutralizing antibody response. However, specific protective 54 components or cooperation between components warrant to be explored in subsequent 55 experiments. In conclusion, this study can provide important evidence for those who live in 56 JEV-endemic areas and are at risk for ZIKV infection.57 4 Introduction 58 Recently, Zika virus (ZIKV) has caused devastating outbreaks of fetal congenital 59 malformations in South and Central America and now transmitted in more than 70 60 countries, including many previously unaffected regions. ZIKV infection during pregnancy 61 increases the risk of neurological disorders in newborns (1), such as microcephaly. In 62 adults, ZIKV causes Guillain-Barré syndrome and other neurologic disorders (2). So far, 63 no specific vaccine or antiviral for prevention and treatment of Z...

show abstract

“…S2B). This level of sensitivity was achieved by using a customised mosquito rRNA depletion, which helped to achieve a higher portion of viral sequencing reads (11.7-17.3%) compared to other metatranscriptomic studies where mosquito pool samples had as little as <1% viral reads [45][46][47] . Notably, the rRNA depletion was effective only when a higher concentration of the customised probe mixture was used than advised in the manufacturer's instructions (Fig.…”

Section: Discussionmentioning

confidence: 99%

Sensitivity and specificity of metatranscriptomics as an arbovirus surveillance tool

Batovska

Mee

Lynch

et al. 2019

Sci Rep

View full text Add to dashboard Cite

be established for routine use of metatranscriptomic sequencing. The criterion for positive detection of a virus established in this paper is one example of a process that can be applied to produce comparable results, which also accounts for potential contamination found in the negative control. Further work utilising wild caught mosquitoes from diverse populations will help to establish metatranscriptomic sequencing as a tool that can broaden the capabilities of arbovirus surveillance.

show abstract

Metagenomic Analysis of Flaviviridae in Mosquito Viromes Isolated From Yunnan Province in China Reveals Genes From Dengue and Zika Viruses

Cited by 33 publications

References 42 publications

T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine

T cell immunity rather than antibody mediates cross-protection against Zika virus infection conferred by a live attenuated Japanese encephalitis SA14-14-2 vaccine

Cross-Protection Against Zika Virus Infection Conferred by a Live Attenuated Japanese Encephalitis SA14-14-2 Vaccine

Sensitivity and specificity of metatranscriptomics as an arbovirus surveillance tool

Contact Info

Product

Resources

About